Objectives To assess the safety and efficacy of interleukin (IL)− 6 blockade with sarilumab in
patients with severe COVID-19 pneumonia and systemic hyperinflammation. Methods We …

Objectives The purpose of this study is to test the safety and effectiveness of individually or
simultaneously blocking IL-6, IL-6 receptor and IL-1 versus standard of care on blood …

Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed …

Objective Severely ill COVID-19 patients may end in acute respiratory distress syndrome
(ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state …

The COVID-19 pandemic, caused by the spread of severe acute respiratory syndrome
coronavirus 2, has resulted in more than 1· 8 million deaths worldwide as of Jan 7, 2021, a …

The Lancet, 3 we described how BenevolentAI's proprietary artificial intelligence (AI)-derived
knowledge graph, 4 queried by a suite of algorithms, enabled identification of a target and a …

Abstract Treatment with immunomodulators, such as intravenous immunoglobulin (IVIG),
may attenuate inflammatory responses observed in the severe stages of acute respiratory …

Introduction A large proportion of patients with COVID-19 develop acute kidney injury (AKI).
While the most severe of these cases require renal replacement therapy (RRT), little is …

The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global
pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe …

Background Published randomized controlled trials are underpowered for binary clinical
end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in …